Browsing by Author "Prasher, Parteek"

Now showing 1 - 9 of 9
  • No Thumbnail Available
    Item
    Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1α
    (2020) Aljabali, Alaa A. A.; Bakshi, Hamid A.; Hakkim, Faruck L.; Haggag, Yusuf A.; Al-Batanyeh, Khalid M.; Al Zoubi, Mazhar S.; Al-Trad, Bahaa; Nasef, Mohamed M.; Satija, Saurabh; Mehta, Meenu; Pabreja, Kavita; Mishra, Vijay; Khan, Mohammed; Abobaker, Salem; Azzouz, Ibrahim M.; Dureja, Harish; Pabari, Ritesh M.; Dardouri, Ashref Ali K.; Kesharwani, Prashant; Gupta, Gaurav; Shukla, Shakti Dhar; Prasher, Parteek; Charbe, Nitin B.; Negi, Poonam; Kapoor, Deepak N.; Chellappan, Dinesh Kumar; da Silva, Mateus Webba; Thompson, Paul; Dua, Kamal; McCarron, Paul; Tambuwala, Murtaza M.
    Piceatannol (PIC) is known to have anticancer activity, which has been attributed to its ability to block the proliferation of cancer cells via suppression of the NF-kB signaling pathway. However, its effect on hypoxia-inducible factor (HIF) is not well known in cancer. In this study, PIC was loaded into bovine serum albumin (BSA) by desolvation method as PIC-BSA nanoparticles (NPs). These PIC-BSA nanoparticles were assessed for in vitro cytotoxicity, migration, invasion, and colony formation studies and levels of p65 and HIF-1 alpha. Our results indicate that PIC-BSA NPs were more effective in downregulating the expression of nuclear p65 and HIF-1 alpha in colon cancer cells as compared to free PIC. We also observed a significant reduction in inflammation induced by chemical colitis in mice by PIC-BSA NPs. Furthermore, a significant reduction in tumor size and number of colon tumors was also observed in the murine model of colitis-associated colorectal cancer, when treated with PIC-BSA NPs as compared to free PIC. The overall results indicate that PIC, when formulated as PIC-BSA NPs, enhances its therapeutic potential. Our work could prompt further research in using natural anticancer agents as nanoparticels with possible human clinical trails. This could lead to the development of a new line of safe and effective therapeutics for cancer patients.
  • No Thumbnail Available
    Item
    An overview of vaccine development for COVID-19
    (2021) Shahcheraghi, Seyed H.; Ayatollahi, Jamshid; Aljabali, Alaa A. A.; Shastri, Madhur D.; Shukla, Shakti D.; Chellappan, Dinesh K.; Jha, Niraj K.; Anand, Krishnan; Katari, Naresh K.; Mehta, Meenu; Satija, Saurabh; Dureja, Harish; Mishra, Vijay; Almutary, Abdulmajeed G.; Alnuqaydan, Abdullah M.; Charbe, Nitin; Prasher, Parteek; Gupta, Gaurav; Dua, Kamal; Lotfi, Marzieh; Bakshi, Hamid A.; Tambuwala, Murtaza M.
    The COVID-19 pandemic continues to endanger world health and the economy. The causative SARS-CoV-2 coronavirus has a unique replication system. The end point of the COVID-19 pandemic is either herd immunity or widespread availability of an effective vaccine. Multiple candidate vaccines - peptide, virus-like particle, viral vectors (replicating and nonreplicating), nucleic acids (DNA or RNA), live attenuated virus, recombinant designed proteins and inactivated virus - are presently under various stages of expansion, and a small number of vaccine candidates have progressed into clinical phases. At the time of writing, three major pharmaceutical companies, namely Pfizer and Moderna, have their vaccines under mass production and administered to the public. This review aims to investigate the most critical vaccines developed for COVID-19 to date.
  • No Thumbnail Available
    Item
    Dietary Crocin is Protective in Pancreatic Cancer while Reducing Radiation-Induced Hepatic Oxidative Damage
    (2020) Bakshi, Hamid A.; Al Zoubi, Mazhar S.; Faruck, Hakkim L.; Aljabali, Alaa A. A.; Rabi, Firas A.; Hafiz, Amin A.; Al-Batanyeh, Khalid M.; Al-Trad, Bahaa; Ansari, Prawej; Nasef, Mohamed M.; Charbe, Nitin B.; Satija, Saurabh; Mehta, Meenu; Mishra, Vijay; Gupta, Gaurav; Abobaker, Salem; Negi, Poonam; Azzouz, Ibrahim M.; Dardouri, Ashref Ali K.; Dureja, Harish; Prasher, Parteek; Chellappan, Dinesh K.; Dua, Kamal; Da Silva, Mateus Webba; El Tanani, Mohamed; McCarron, Paul A.; Tambuwala, Murtaza M.
    Pancreatic cancer is one of the fatal causes of global cancer-related deaths. Although surgery and chemotherapy are standard treatment options, post-treatment outcomes often end in a poor prognosis. In the present study, we investigated anti-pancreatic cancer and amelioration of radiation-induced oxidative damage by crocin. Crocin is a carotenoid isolated from the dietary herb saffron, a prospect for novel leads as an anti-cancer agent. Crocin significantly reduced cell viability of BXPC3 and Capan-2 by triggering caspase signaling via the downregulation of Bcl-2. It modulated the expression of cell cycle signaling proteins P53, P21, P27, CDK2, c-MYC, Cyt-c and P38. Concomitantly, crocin treatment-induced apoptosis by inducing the release of cytochrome c from mitochondria to cytosol. Microarray analysis of the expression signature of genes induced by crocin showed a substantial number of genes involved in cell signaling pathways and checkpoints (723) are significantly affected by crocin. In mice bearing pancreatic tumors, crocin significantly reduced tumor burden without a change in body weight. Additionally, it showed significant protection against radiation-induced hepatic oxidative damage, reduced the levels of hepatic toxicity and preserved liver morphology. These findings indicate that crocin has a potential role in the treatment, prevention and management of pancreatic cancer.
  • Thumbnail Image
    Item
    Luteolin: a favonoid with a multifaceted anticancer potential
    (2022) Prasher, Parteek; Sharma, Mousmee; Singh, Sachin K.; Gulati, Monica; Chellappan, Dinesh K.; Zacconi, Flavia C. M.; De Rubis, Gabriele; Gupta, Gaurav; Sharifi-Rad, Javad; Cho, William C.; Dua, Kamal
    Therapeutic effect of phytochemicals has been emphasized in the traditional medicine owing to the presence of bioactive molecules, such as polyphenols. Luteolin is a flavone belonging to the flavonoid class of polyphenolic phytochemicals with healing effect on hypertension, inflammatory disorders, and cancer due to its action as pro-oxidants and antioxidants. The anticancer profile of luteolin is of interest due to the toxic effect of contemporary chemotherapy paradigm, leading to the pressing need for the development and identification of physiologically benevolent anticancer agents and molecules. Luteolin exerts anticancer activity by downregulation of key regulatory pathways associated with oncogenesis, in addition to the induction of oxidative stress, cell cycle arrest, upregulation of apoptotic genes, and inhibition of cell proliferation and angiogenesis in cancer cells. In this review, we discuss about the anticancer profile of luteolin.
  • No Thumbnail Available
    Item
    Probing 3CL protease: Rationally designed chemical moieties for COVID-19
    (2020) Sharma, Mousmee; Prasher, Parteek; Mehta, Meenu; Zacconi, Flavia C.; Singh, Yogendra; Kapoor, Deepak N.; Dureja, Harish; Pardhi, Dinesh M.; Tambuwala, Murtaza M.; Gupta, Gaurav; Chellappan, Dinesh K.; Dua, Kamal; Satija, Saurabh
  • Thumbnail Image
    Item
    Protein and peptide delivery to lungs by using advanced targeted drug delivery
    (2022) Chellappan, Dinesh Kumar; Prasher, Parteek; Saravanan, Vilashini; Yee, Vanessa See Vern; Chi, Wendy Chai Wen; Wong, Jia Wei; Wong, Joon Kang; Wong, Jing Tong; Wan, Wai; Chellian, Jestin; Molugulu, Nagashekhara; Prabu, Sakthivel Lakshmana; Ibrahim, Rania; Darmarajan, Thiviya; Candasamy, Mayuren; Singh, Pankaj Kumar; Mishra, Vijay; Shastri, Madhur D.; Zacconi, Flavia C. M.; Chakraborty, Amlan; Mehta, Meenu; Gupta, Piyush Kumar; Dureja, Harish; Gulati, Monica; Singh, Sachin Kumar; Gupta, Gaurav; Jha, Niraj Kumar; Oliver, Brian Gregory George; Dua, Kamal
    The challenges and difficulties associated with conventional drug delivery systems have led to the emergence of novel, advanced targeted drug delivery systems. Therapeutic drug delivery of proteins and peptides to the lungs is complicated owing to the large size and polar characteristics of the latter. Nevertheless, the pulmonary route has attracted great interest today among formulation scientists, as it has evolved into one of the important targeted drug delivery platforms for the delivery of peptides, and related compounds effectively to the lungs, primarily for the management and treatment of chronic lung diseases. In this review, we have discussed and summarized the current scenario and recent developments in targeted delivery of proteins and peptide-based drugs to the lungs. Moreover, we have also highlighted the advantages of pulmonary drug delivery over conventional drug delivery approaches for peptide-based drugs, in terms of efficacy, retention time and other important pharmacokinetic parameters. The review also highlights the future perspectives and the impact of targeted drug delivery on peptide-based drugs in the coming decade.
  • No Thumbnail Available
    Item
    Targeting LIN28: a new hope in prostate cancer theranostics
    (2021) Shrivastava, Garima; Aljabali, Alaa A. A.; Shahcheraghi, Seyed Hossein; Lotfi, Marzieh; Shastri, Madhur D.; Shukla, Shakti D.; Chellappan, Dinesh K.; Jha, Niraj Kumar; Anand, Krishnan; Dureja, Harish; Pabari, Ritesh M.; Mishra, Vijay; Almutary, Abdulmajeed G.; Alnuqaydan, Abdullah M.; Charbe, Nitin; Prasher, Parteek; Negi, Poonam; Goyal, Rohit; Dua, Kamal; Gupta, Gaurav; Serrano-Aroca, Angel; Bahar, Bojlul; Barh, Debmalya; Panda, Pritam Kumar; Takayama, Kazuo; Lundstorm, Kenneth; McCarron, Paul; Bakshi, Hamid; Tambuwala, Murtaza M.
    The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area.
  • Thumbnail Image
    Item
    Targeting mucus barrier in respiratory diseases by chemically modified advanced delivery systems
    (ELSEVIER IRELAND LTD, 2022) Prasher, Parteek; Sharma, Mousmee; Singh, Sachin Kumar; Gulati, Monica; Jha, Niraj Kumar; Gupta, Piyush Kumar; Gupta, Gaurav; Chellappan, Dinesh Kumar; Zacconi, Flavia C. M.; Pinto, Terezinha de Jesus Andreoli; Chan, Yinghan; Liu, Gang; Paudel, Keshav Raj; Hansbro, Philip M.; Oliver, Brian Gregory George; Dua, Kamal
    Mucus gel constitutes of heavily cross-linked mucin fibers forming a viscoelastic, dense porous network that coats all the exposed epithelia not covered with the skin. The layer provides protection to the underlying gastrointestinal, respiratory, and female reproductive tracts, in addition to the organs such as the surface of eye by trapping the pathogens, irritants, environmental fine particles, and potentially hazardous foreign matter. However, this property of mucus gel poses a substantial challenge for realizing the localized and sustained drug delivery across the mucosal surfaces. The mucus permeating particles that spare the protective properties of mucus gel improve the therapeutic potency of the drugs aimed at the management of diseases, including sexually transmitted infections, lung cancer, irritable bowel disease, degenerative eye diseases and infections, and cystic fibrosis. As such, the mucoadhesive materials conjugated with drug molecules display a prolonged retention time in the mucosal gel that imparts a sustained release of the deliberated drug molecules across the mucosa. The contemporarily developed mucus penetrating materials for drug delivery applications comprise of a finer size, appreciable hydrophilicity, and a neutral surface to escape the entrapment within the cross-inked mucus fibers. Pertaining to the mucus secretion as a first line of defence in respiratory tract in response to the invading physical, chemical, and biological pathogens, the development of mucus penetrating materials hold promise as a stalwart approach for revolutionizing the respiratory drug delivery paradigm. The present review provides an epigrammatic collation of the mucus penetrating/mucoadhesive materials for achieving a controlled/sustained release of the cargo pharmaceutics and drug molecules across the respiratory mucus barrier.
  • Thumbnail Image
    Item
    Toward the cholinesterase inhibition potential of TADDOL derivatives: Seminal biological and computational studies
    (2022) Constantino, Andrea R.; Charbe, Nitin Bharat; Duarte, Yorley; Gutierrez, Margarita; Giordano Villatoro, Ady; Prasher, Parteek; Dua, Kamal; Mandolesi, Sandra; Zacconi, Flavia C. M.
    Alzheimer's disease (AD) is a degenerative neurological disease characterized by gradual loss of cognitive skills and memory. The exact pathogenesis involved still remains unrevealed, but several studies indicate the involvement of an array of different enzymes, underlining the multifactorial character of the disease. Inhibition of these enzymes is therefore a powerful approach in the development of AD treatments, with promising candidates, including acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and monoamine oxidase. Interestingly, AChE is the target of a major pesticide family (organophosphates), with several reports indicating an intersection between the pesticide's activity and AD. In this study, various TADDOL derivatives were synthesized and their in vitro activities as AChE/BuChE inhibitors as well as their antioxidant activities were studied. Molecular modeling studies revealed the capability of TADDOL derivatives to bind to AChE and induce inhibition, especially compounds 2b and 3c furnishing IC50 values of 36.78 +/- 8.97 and 59.23 +/- 5.31 mu M, respectively. Experimental biological activities and molecular modeling studies clearly demonstrate that TADDOL derivatives with specific stereochemistry have an interesting potential for the design of potent AChE inhibitors. The encouraging results for compounds 2b and 3c indicate them as promising scaffolds for selective and potent AChE inhibitors.